Sepsis Diagnostics Market is expected to reach US$ 1,226.52 million by 2028

The sepsis diagnostics market is projected to reach US$ 1,226.52 million by 2028; registering at a CAGR of 9.2% from 2021 to 2028, according to a new research study conducted by The Insight Partners

The report highlights the key factors driving the market and prominent players with their developments.

The sepsis diagnostics market growth is attributed to the high incidence of sepsis due to increasing nosocomial infections and rise in demand for rapid diagnostic tests leading to increasing product launches. However, the lack of skilled professionals hampers the market growth.

By product type, the sepsis diagnostics market is segmented into instrument, reagent and assay, blood culture media, and software. In 2021, the blood culture media segment held the largest market share. Moreover, the software segment is anticipated to register the highest CAGR during the forecast period.

By technology, the sepsis diagnostics market is segmented into molecular diagnostics, flow cytometry, microfluidics, immunoassay, biomarkers, and microbiology. The molecular diagnostics segment is further segmented into polymerase chain reaction, peptide nucleic acid-fluorescent in situ hybridization, syndromic panel-based testing, and microarray. The microbiology segment held the largest market share in 2021. However, the molecular diagnostics segment is anticipated to register the highest CAGR during the forecast period.

By method, the sepsis diagnostics market is bifurcated into automated diagnostics and conventional diagnostics. In 2021, the conventional diagnostics segment held a larger sepsis diagnostics market share. However, the automated diagnostics segment is anticipated to register a higher CAGR during the forecast period.

By test type, the sepsis diagnostics market is bifurcated into point-of-care tests and laboratory tests. In 2021, the laboratory tests segment held a larger sepsis diagnostics market share. However, the point-of-care tests segment is anticipated to register a higher CAGR during the forecast period.

By pathogen, the sepsis diagnostics market is segmented into bacterial sepsis, fungal sepsis, and other. The bacterial sepsis segment held the largest market share in 2021 and is projected to register the highest CAGR during the forecast period.

By end user, the sepsis diagnostics market is segmented into hospitals, pathology and reference laboratories, and others. The hospitals segment held the largest market share in 2021. However, the pathology and reference laboratories segment is anticipated to register the highest CAGR during the forecast period.

Sepsis Diagnostics Market, by Region, 2021 (%)

Market Insights

High Incidence of Sepsis due to Increasing Nosocomial Infections

Infection is the root cause of sepsis. Sepsis mainly occurs in immunocompromised people, such as those taking chemotherapy, having a splenectomy, and suffering from AIDS and chronic illnesses like diabetes. Among several types of infections, nosocomial infections are the primary cause of morbidity and mortality among hospitalized patients. For instance, according to the "2020 National and State Healthcare-Associated Infections Progress Report", published by the Centers for Disease Control and Prevention (CDC) in 2021, about 24%, 35%, and 15% increase was recorded in central line-associated bloodstream infections, ventilator-associated events, and Methicillin-resistant Staphylococcus Aureus (MRSA) bacteremia, respectively, in the US between 2019 and 2020. Additionally, as per a report published by the Global Sepsis Alliance (GSA), nearly 26 million people develop sepsis every year, and approximately 8 million patients die because of sepsis globally. Thus, the rising bloodstream infections will increase the adoption of sepsis diagnostic products.

Sepsis has a high mortality and morbidity rate. According to an article published by the National Center for Biotechnology Information (NCBI) in February 2019, it was estimated that the mortality rate of sepsis was 25–30%. Additionally, in September 2020, World Health Organization (WHO) estimated that each year almost 50% cases of sepsis occur among children, resulting in 2.9 million deaths. Most deaths can be prevented through early diagnosis and appropriate clinical management. These deaths are often a consequence of diarrheal diseases or lower respiratory infections. Thus, the high incidence rate of sepsis is expected to boost the demand for sepsis diagnostic products, thereby supporting the sepsis diagnostics market growth during the forecast period.

Impact Analysis of COVID-19 Pandemic: Sepsis Diagnostics Market

Before the COVID-19 pandemic, the sepsis diagnostics market was stabilized and experienced a steady growth. During the pandemic, all the major regions had the vigorous response regarding sepsis, as sepsis was a common condition and the main cause of deaths for COVID-19 patients. As per European Sepsis Alliance Report 2021, 78% of COVID-19 patients treated in ICU and around 34% in the general ward experienced sepsis. Sepsis and COVID-19 patients experience consumptive thrombocytopenia, haemolytic anaemia, vascular microthrombosis, multi-organ dysfunction syndrome, coagulopathy, septic shock, respiratory failure, fever, leukopenia, hypotension, leukocytosis, high cytokine production, and high predisposition to opportunistic infections.

Further, the COVID-19 pandemic had a positive effect on the sales of diagnostics products for sepsis. The rapid virus spread that causes COVID-19 and the emerging cases of sepsis among COVID-19 patients increased the demand for rapid diagnosis, accelerating the utilization of instruments, reagents, and assay kits for the detection of sepsis. Thus, increasing need for early diagnosis of sepsis among COVID-19 patients propels the demand for diagnostics and drives the market growth significantly.

Competitive Landscape: Sepsis Diagnostics Market

Product launches and approvals are among the most commonly adopted strategies by companies to expand their global footprints and product portfolios. Market players also focus on the partnership strategy to enlarge their clientele, which, in turn, permits them to maintain their brand name across the world. Abbott; F. HOFFMANN-LA ROCHE LTD.; Immunexpress Inc.; BD; Danaher; Luminex Corporation; THERMO FISHER SCIENTIFIC INC.; bioMerieux SA; T2 Biosystems, Inc.; and Axis-Shield Diagnostics Ltd are among the leading companies operating in the sepsis diagnostics market growth.   

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com